Yeji

$RLAY

Relay Therapeutics, Inc.

Runway:12 mo
NasdaqMarket cap: —CIK 0001812364

Upcoming catalysts

0 surfaced

No catalysts surfaced for RLAY yet.

Drug pipeline

zovegalisib
adults with PIK3CA mutant hormone receptor positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) locally advanced or metastatic breast cancer following recurrence or progression on or after treatment with a CDK4/6 inhibitor
RLY-5836
PIK3CA Mutation
RLY-2608
PIK3CA Mutation
RLY-8161
NRAS Mutation

Recent & active trials

NCTDrugPhaseStatusPrimary completion
NCT06789913RLY-2608Phase 2Recruiting2031-07-01
NCT06982521RLY-2608Phase 3Recruiting2028-04-30
NCT07584226RLY-8161Phase 1Recruiting2027-12-30
NCT05216432RLY-2608Phase 1Recruiting2027-04-30
NCT05759949RLY-5836Phase 1Completed2025-03-18

Recent catalysts

FDA approvalFeb 3, 2026· 123d ago
$RLAYRelay Therapeutics, Inc.
zovegalisib · adults with PIK3CA mutant hormone receptor positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) locally advanced or metastatic breast cancer following recurrence or progression on or after treatment with a CDK4/6 inhibitor
“On February 3, 2026, the Company announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation to zovegalisib (RLY-2608) in combination with fulvestrant for the treatment of adults with PIK3CA mutant hormone receptor positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) locally advanced or metastatic breast cancer following recurrence or progression on or after treatment with a CDK4/6 inhibitor.”